GeneTex

  • Country / Location Selection

United States (US)

SARS-CoV-2 (COVID-19) Nucleocapsid antibody

Orthogonal
Anti-SARS-CoV-2 (COVID-19) Nucleocapsid antibody used in ELISA (ELISA). GTX135357
Anti-SARS-CoV-2 (COVID-19) Nucleocapsid antibody used in ELISA (ELISA). GTX135357
Anti-SARS-CoV-2 (COVID-19) Nucleocapsid antibody used in Flow cytometry (FACS). GTX135357
Anti-SARS-CoV-2 (COVID-19) Nucleocapsid antibody used in Western Blot (WB). GTX135357
Anti-SARS-CoV-2 (COVID-19) Nucleocapsid antibody used in IHC-P (cell pellet) (IHC-P (cell pellet)). GTX135357
Anti-SARS-CoV-2 (COVID-19) Nucleocapsid antibody used in Immunocytochemistry/ Immunofluorescence (ICC/IF). GTX135357
Anti-SARS-CoV-2 (COVID-19) Nucleocapsid antibody used in ELISA (ELISA). GTX135357
Anti-SARS-CoV-2 (COVID-19) Nucleocapsid antibody used in Western Blot (WB). GTX135357
Anti-SARS-CoV-2 (COVID-19) Nucleocapsid antibody used in IHC-P (cell pellet) (IHC-P (cell pellet)). GTX135357
Anti-SARS-CoV-2 (COVID-19) Nucleocapsid antibody used in Immunoprecipitation (IP). GTX135357
Anti-SARS-CoV-2 (COVID-19) Nucleocapsid antibody used in Western Blot (WB). GTX135357

Cat. No. GTX135357

Reference 129
5

Host

 Rabbit

Clonality

 Polyclonal

Isotype

 IgG

Application

 WB, ICC/IF, IHC-P, IHC-Fr, FACS, IP, ELISA, Blocking, IHC, Sandwich ELISA, IHC-P (cell pellet)

Reactivity

 SARS Coronavirus, SARS Coronavirus 2
Package
100 μl ($399),
25 μl ($169)
See all SARS-CoV-2 (COVID-19) nucleocapsid products

APPLICATION

Application Note

*Optimal dilutions/concentrations should be determined by the researcher.
Application Recommended Dilution
WB 1:1000-1:10000
ICC/IF 1:100-1:1000
IHC-P 1:100-1:1000
IHC-Fr Assay dependent
FACS Assay dependent
IP 1:100-1:5000
ELISA Assay dependent
Blocking Assay dependent
IHC Assay dependent
Sandwich ELISA Assay dependent
IHC-P (cell pellet) Assay dependent

Note :

Sandwich ELISA
Capture : GTX632269 / GTX135357, Detection : GTX135357 / GTX632269
Not tested in other applications.

Product Note

This antibody detects SARS-CoV-2 nucleocapsid protein. Our internal testing indicates cross-reactivity with SARS-CoV nucleocapsid protein, but not with MERS-CoV nucleocapsid protein.

PROPERTIES

Form

Liquid

Buffer

1XPBS (pH7), 20% Glycerol

Preservative

0.025% ProClin 300

Storage

Store as concentrated solution. Centrifuge briefly prior to opening vial. For short-term storage (1-2 weeks), store at 4ºC. For long-term storage, aliquot and store at -20ºC or below. Avoid multiple freeze-thaw cycles.

Concentration

0.33 mg/ml (Please refer to the vial label for the specific concentration.)

Antigen Species

SARS Coronavirus 2

Immunogen

Full length SARS-CoV-2 (COVID-19) nucleocapsid Recombinant protein. (SARS-CoV-2 (strain Wuhan-Hu-1))

Purification

Purified by antigen-affinity chromatography.

Conjugation

Unconjugated

RRID

AB_2868464

Note

For In vitro laboratory use only. Not for any clinical, therapeutic, or diagnostic use in humans or animals. Not for animal or human consumption.

TARGET

Synonyms

2019-nCoV Nucleocapsid , SARS-CoV-2 Nucleocapsid , COVID-19 Nucleocapsid , 2019-nCoV NP , SARS-CoV-2 NP , COVID-19 NP

Research Area

DATA IMAGES

Anti-SARS-CoV-2 (COVID-19) Nucleocapsid antibody used in ELISA (ELISA). GTX135357

GTX135357 ELISA Image

Sandwich ELISA detection of recombinant full-length SARS-CoV-2 (COVID-19) nucleocapsid protein (GTX135357-pro) using GTX135357 as capture antibody at concentration of 5 μg/mL and GTX632269 as detection antibody at concentration of 1 μg/mL. Mouse IgG antibody (HRP) (GTX213111-01) was diluted at 1:10000 and used to detect the primary antibody.

Anti-SARS-CoV-2 (COVID-19) Nucleocapsid antibody used in ELISA (ELISA). GTX135357

GTX135357 ELISA Image

Indirect ELISA analysis was performed by coating plate with 50 μL of recombinant full-length SARS-CoV-2 (COVID-19) nucleocapsid protein (GTX135357-pro) at concentrations ranging from 0.0625 μg/mL to 4 μg/mL. The coated protein is detected with SARS-CoV-2 (COVID-19) nucleocapsid antibody (GTX135357) at 1 μg/mL. Rabbit IgG antibody (HRP) (GTX213110-01) was diluted at 1:10000 and used to detect the primary antibody.

Anti-SARS-CoV-2 (COVID-19) Nucleocapsid antibody used in Flow cytometry (FACS). GTX135357

GTX135357 FACS Image

SARS-CoV-2 (COVID-19) nucleocapsid antibody (GTX135357) detects SARS-CoV-2 (COVID-19) nucleocapsid by flow cytometry analysis.
Sample: Vero E6 cells infected with SARS-CoV-2.
Black: Uninfected Vero E6 cells was used as a control.
Red: SARS-CoV-2 (COVID-19) nucleocapsid antibody (GTX135357) dilution: 1:100.
Anti-SARS-CoV-2 (COVID-19) Nucleocapsid antibody used in Western Blot (WB). GTX135357

GTX135357 WB Image

Non-transfected (–) and transfected (+) 293T whole cell extracts (30 μg) were separated by 10% SDS-PAGE, and the membrane was blotted with SARS-CoV-2 (COVID-19) nucleocapsid antibody (GTX135357) diluted at 1:5000. The HRP-conjugated anti-rabbit IgG antibody (GTX213110-01) was used to detect the primary antibody.

Anti-SARS-CoV-2 (COVID-19) Nucleocapsid antibody used in IHC-P (cell pellet) (IHC-P (cell pellet)). GTX135357

GTX135357 IHC-P (cell pellet) Image

SARS-CoV-2 (COVID-19) nucleocapsid antibody detects SARS-CoV-2 (COVID-19) nucleocapsid protein by immunohistochemical analysis.
Sample: Mock (GTX435670) and SARS-CoV-2 (COVID-19) Nucleocapsid transfected 293T cell FFPE Cell Pellet Block (GTX435641).
Green: SARS-CoV-2 (COVID-19) nucleocapsid stained by SARS-CoV-2 (COVID-19) nucleocapsid antibody (GTX135357) diluted at 1:1000.
Blue: Fluoroshield with DAPI (GTX30920).
Antigen Retrieval: Citrate buffer, pH 6.0, 15 min

Anti-SARS-CoV-2 (COVID-19) Nucleocapsid antibody used in Immunocytochemistry/ Immunofluorescence (ICC/IF). GTX135357

GTX135357 ICC/IF Image

SARS-CoV-2 (COVID-19) nucleocapsid antibody detects SARS-CoV-2 (COVID-19) nucleocapsid protein by immunofluorescent analysis.
Sample: Mock and transfected 293T cells were fixed in 4% paraformaldehyde at RT for 15 min.
Green: SARS-CoV-2 (COVID-19) nucleocapsid stained by SARS-CoV-2 (COVID-19) nucleocapsid antibody (GTX135357) diluted at 1:1000.
Blue: Fluoroshield with DAPI (GTX30920).

Anti-SARS-CoV-2 (COVID-19) Nucleocapsid antibody used in ELISA (ELISA). GTX135357

GTX135357 ELISA Image

Sandwich ELISA detection of non-transfected (GTX535673) and SARS-CoV-2 nucleocapsid (full length) transfected (GTX535665) 293T whole cell extracts using SARS-CoV / SARS-CoV-2 (COVID-19) nucleocapsid antibody [6H3] (GTX632269) as capture antibody at concentration of 5 μg/mL and SARS-CoV-2 (COVID-19) nucleocapsid antibody (GTX135357) as detection antibody at concentration of 1 μg/mL. Rabbit IgG antibody (HRP) (GTX213110-01) was diluted at 1:10000 and used to detect the primary antibody.

Anti-SARS-CoV-2 (COVID-19) Nucleocapsid antibody used in Western Blot (WB). GTX135357

GTX135357 WB Image

Non-transfected (–) and transfected (+) Vero E6 whole cell extracts (30 μg) were separated by 10% SDS-PAGE, and the membrane was blotted with SARS-CoV-2 (COVID-19) nucleocapsid antibody (GTX135357) diluted at 1:5000. The HRP-conjugated anti-rabbit IgG antibody (GTX213110-01) was used to detect the primary antibody.

Anti-SARS-CoV-2 (COVID-19) Nucleocapsid antibody used in IHC-P (cell pellet) (IHC-P (cell pellet)). GTX135357

GTX135357 IHC-P (cell pellet) Image

SARS-CoV-2 (COVID-19) nucleocapsid antibody detects SARS-CoV-2 (COVID-19) nucleocapsid protein by immunohistochemical analysis.
Sample: Paraffin-embedded SARS-CoV-2 (COVID-19) Nucleocapsid FFPE Cell Pellet Block.
Green: SARS-CoV-2 (COVID-19) nucleocapsid stained by SARS-CoV-2 (COVID-19) nucleocapsid antibody (GTX135357) diluted at 1:1000.
Red: SARS-CoV / SARS-CoV-2 (COVID-19) nucleocapsid stained by SARS-CoV / SARS-CoV-2 (COVID-19) nucleocapsid antibody [6H3] (GTX632269) diluted at 1:1000.
Blue: Fluoroshield with DAPI (GTX30920).
Antigen Retrieval: Citrate buffer, pH 6.0, 15 min

Anti-SARS-CoV-2 (COVID-19) Nucleocapsid antibody used in Immunoprecipitation (IP). GTX135357

GTX135357 IP Image

Immunoprecipitation of SARS-CoV-2 (COVID-19) nucleocapsid protein from SARS-CoV-2 (2019-nCoV) NP-transfected 293T whole cell extract using 1 μg of SARS-CoV-2 (COVID-19) nucleocapsid antibody (GTX135357).
Western blot analysis was performed using SARS-CoV-2 (COVID-19) nucleocapsid antibody (GTX135357).
EasyBlot HRP-conjugated anti rabbit IgG antibody (GTX221666-01).

Anti-SARS-CoV-2 (COVID-19) Nucleocapsid antibody used in Western Blot (WB). GTX135357

GTX135357 WB Image

Non-transfected (–) and transfected (+) 293T whole cell extracts (30 μg) were separated by 10% SDS-PAGE, and the membrane was blotted with SARS-CoV-2 (COVID-19) nucleocapsid antibody (GTX135357) diluted at 1:5000. The HRP-conjugated anti-rabbit IgG antibody (GTX213110-01) was used to detect the primary antibody.

REFERENCE

Application Reference

N Schmidt et al. Cell 2023; SND1 binds SARS-CoV-2 negative-sense RNA and promotes viral RNA synthesis through NSP9
Application : IP
Flamier A et al. iScience 2023; 26 (9) : 107690 Human iPS cell-derived sensory neurons can be infected by SARS-CoV-2.
Li M et al. mBio 2023; 14 (4) : e0119423 SARS-CoV-2 ORF6 protein does not antagonize interferon signaling in respiratory epithelial Calu-3 cells during infection.
C Di Primio et al. PNAS Nexus 2023; 2 (9) : pgad282 Severe acute respiratory syndrome coronavirus 2 infection leads to Tau pathological signature in neurons
Application : WB, ICC/IF
Lee D et al. Science 2023; 379 (6632) : eabo3627 Inborn errors of OAS-RNase L in SARS-CoV-2-related multisystem inflammatory syndrome in children.
Show More +
Submit a Reference

REVIEW

SARS-CoV-2 (COVID-19) Nucleocapsid antibody Cat. No. GTX135357

Rating
( Average 5 based on 5 users reviews)
Application
Western Blot(WB)
( Average 5 based on 2 users reviews)
IHC (Paraffin sections)(IHC-P)
( Average 5 based on 2 users reviews)
Flow cytometry(FACS)
( Average 5 based on 1 users reviews)
Anti-SARS-CoV-2 (COVID-19) Nucleocapsid antibody used in IHC (Paraffin sections) (IHC-P). GTX135357
Date : Anonymous submitted on 24-Jul-2023
Score :
Application Tested : IHC-P
Figure Note : The data was peer reviewed and published in the 2022 in Front Cell Infect Microbiol. PMID: 35770069
Anti-SARS-CoV-2 (COVID-19) Nucleocapsid antibody used in Western Blot (WB). GTX135357
Date : Anonymous submitted on 03-Oct-2022
Score :
Application Tested : WB
Figure Note : The data was peer reviewed and published in the 2020 in Int J Mol Sci. PMID: 33233817
Anti-SARS-CoV-2 (COVID-19) Nucleocapsid antibody used in Western Blot (WB). GTX135357
Date : Anonymous submitted on 03-Aug-2022
Score :
Application Tested : WB
Sample Species : SARS-CoV-2
Sample : SUMO tagged recombinant SARS-CoV-2 (COVID-19) nucleocapsid protein (NP49-174aa) with/without IPTG induction
Amount used : 30μg
Blocking : 5% non-fat milk in PBST, RT, 0.5Hr
Primary Antibody : 1:1000, 25°C, 1Hr
Anti-SARS-CoV-2 (COVID-19) Nucleocapsid antibody used in IHC (Paraffin sections) (IHC-P). GTX135357
Date : Anonymous submitted on 07-Mar-2022
Score :
Application Tested : IHC-P
Sample : Huma skin tissue specimen
Blocking : 0.3% H2O2 meta, RT, 0.5Hr
Fixation : 10% formalin
Permeabilization /Antigen retrieval : Citrate buffer (ph 6.0)
Primary Antibody : 1:500, 4°C, > 12Hr
Lane Description : Eczema after vaccinated. The patient was COVID-19 negative.
Anti-SARS-CoV-2 (COVID-19) Nucleocapsid antibody used in Flow cytometry (FACS). GTX135357
Date : Anonymous submitted on 14-Jul-2020
Score :
Application Tested : FACS
Sample Species : SARS-CoV-2
Sample : Vero E6 cells infected with SARS-CoV-2 USA-WA1/2020
Fixation : 4% formaldehyde in PBS
Permeabilization /Antigen retrieval : BD Cytofix/Cytoperm
Primary Antibody : 1:100, 25°C, 0.5Hr
Submit a Review
Application Reference
N Schmidt et al. Cell 2023; SND1 binds SARS-CoV-2 negative-sense RNA and promotes viral RNA synthesis through NSP9
Application : IP
Flamier A et al. iScience 2023; 26 (9):107690 Human iPS cell-derived sensory neurons can be infected by SARS-CoV-2.
Li M et al. mBio 2023; 14 (4):e0119423 SARS-CoV-2 ORF6 protein does not antagonize interferon signaling in respiratory epithelial Calu-3 cells during infection.
C Di Primio et al. PNAS Nexus 2023; 2 (9):pgad282 Severe acute respiratory syndrome coronavirus 2 infection leads to Tau pathological signature in neurons
Application : WB, ICC/IF
Resnick JD et al. bioRxiv 2023; Growth media affects susceptibility of air-lifted human nasal epithelial cell cultures to SARS-CoV2, but not Influenza A, virus infection.
Lee D et al. Science 2023; 379 (6632):eabo3627 Inborn errors of OAS-RNase L in SARS-CoV-2-related multisystem inflammatory syndrome in children.
A Flamier et al. bioRxiv 2023; Human iPS cell-derived sensory neurons can be infected by SARS-CoV-2 strain WA1/2020 as well as variants delta and omicron
Application : ICC/IF
de Melo GD et al. Nat Commun 2023; 14 (1):4485 Neuroinvasion and anosmia are independent phenomena upon infection with SARS-CoV-2 and its variants.
Yang J et al. Nat Microbiol 2023; 8 (1):121-134 Fluorogenic reporter enables identification of compounds that inhibit SARS-CoV-2.
AF Carlin et al. Open Forum Infect Dis 2023; 10 (4):ofad154 Neutralizing Antibody Responses After Severe Acute Respiratory Syndrome Coronavirus 2 BA.2 and BA.2.12.1 Infection Do Not Neutralize BA.4 and BA.5 and Can Be Blunted by Nirmatrelvir/Ritonavir Treatment
Application : Blocking
Pillai S et al. Res Sq 2023; A Novel Viral Assembly Inhibitor Blocks SARS-CoV-2 Replication in Airway Epithelial Cells.
Berry C et al. Commun Med (Lond) 2023; 3 (1):75 Beta-containing bivalent SARS-CoV-2 protein vaccine elicits durable broad neutralization in macaques and protection in hamsters.
Lopez-Orozco J et al. J Mol Biol 2023;:168170 The RNA interference effector protein Argonaute 2 functions as a restriction factor against SARS-CoV-2.
Alena Reguzova et al. Research Square 2023; A novel multi-antigenic parapoxvirus-based vaccine demonstrates efficacy in protecting hamsters and non-human primates against SARS-CoV-2 challenge
Application : WB, ICC/IF
Carlin AF et al. Open Forum Infect Dis 2023; 10 (4):ofad154 Neutralizing Antibody Responses After Severe Acute Respiratory Syndrome Coronavirus 2 BA.2 and BA.2.12.1 Infection Do Not Neutralize BA.4 and BA.5 and Can Be Blunted by Nirmatrelvir/Ritonavir Treatment.
Hastie KM et al. Cell Rep 2023; 42 (5):112421 Potent Omicron-neutralizing antibodies isolated from a patient vaccinated 6?months before Omicron emergence.
NK Routhu et al. Sci Immunol 2023;:eadg7015 Efficacy of mRNA-1273 and Novavax ancestral or BA.1 spike booster vaccines against SARS-CoV-2 BA.5 infection in non-human primates
Application : IHC
Satish Pillai et al. Research Square 2023; A Novel Viral Assembly Inhibitor Blocks SARS-CoV-2 Replication in Airway Epithelial Cells
Application : ICC/IF
F. van der Goot et al. Research Square 2023; SARS-CoV-2 shifts transcription of host gene to increase Spike acylation and boost infectivity
Application : WB
F Zhang et al. Nat Microbiol 2023; Pan-sarbecovirus prophylaxis with human anti-ACE2 monoclonal antibodies
Application : Blocking
Zhang L et al. Viruses 2023; 15 (3) LINE1-Mediated Reverse Transcription and Genomic Integration of SARS-CoV-2 mRNA Detected in Virus-Infected but Not in Viral mRNA-Transfected Cells.
Application : ICC/IF
Carlin AF et al. J Med Chem 2023; 1-O-Octadecyl-2-O-benzyl-sn-glyceryl-3-phospho-GS-441524 (V2043). Evaluation of Oral V2043 in a Mouse Model of SARS-CoV-2 Infection and Synthesis and Antiviral Evaluation of Additional Phospholipid Esters with Enhanced Anti-SARS-CoV-2 Activity.
Application : ICC/IF
S?rensen DM et al. Nat Commun 2023; 14 (1):948 Identification of global inhibitors of cellular glycosylation.
Rosain J et al. Cell 2023; 186 (3):621-645.e33 Human IRF1 governs macrophagic IFN-γ immunity to mycobacteria.
Arai Y et al. iScience 2023; 26 (1):105742 Stimulation of interferon-β responses by aberrant SARS-CoV-2 small viral RNAs acting as retinoic acid-inducible gene-I agonists.
Zekri L et al. Front Immunol 2023; 14:1112505 Novel ACE2 fusion protein with adapting activity against SARS-CoV-2 variants in vitro.
Application : ICC/IF
Ueha R et al. Front Cell Infect Microbiol 2022; 12:1019723 Evidence for the spread of SARS-CoV-2 and olfactory cell lineage impairment in close-contact infection Syrian hamster models.
Application : IHC-P
Yeung ST et al. Front Immunol 2022; 13:1011185 Galectin-9 protects humanized-ACE2 immunocompetent mice from SARS-CoV-2 infection.
Application : ICC/IF
Li D et al. Nat Commun 2022; 13 (1):6309 Breadth of SARS-CoV-2 neutralization and protection induced by a nanoparticle vaccine.
Application : IHC-P
Takeda R et al. Sci Rep 2022; 12 (1):14050 Antiviral effect of cetylpyridinium chloride in mouthwash on SARS-CoV-2.
Application : WB
Gro?e M et al. Viruses 2022; 14 (7) Inhibitors of Deubiquitinating Enzymes Interfere with the SARS-CoV-2 Papain-like Protease and Block Virus Replication In Vitro.
Application : ICC/IF
Pereira de Jesus BA et al. Viruses 2022; 14 (12) In Vitro Diagnostic Assay to Detect SARS-CoV-2-Neutralizing Antibody in Patient Sera Using Engineered ACE-2 Mini-Protein.
Polo-Meg?as D et al. Int J Mol Sci 2022; 23 (24) Exploring Highly Conserved Regions of SARS-CoV-2 Spike S2 Subunit as Targets for Fusion Inhibition Using Chimeric Proteins.
Ogura H et al. Nat Commun 2022; 13 (1):7063 Dysfunctional Sars-CoV-2-M protein-specific cytotoxic T lymphocytes in patients recovering from severe COVID-19.
Lista MJ et al. J Virol 2022; 96 (23):e0125022 The P681H Mutation in the Spike Glycoprotein of the Alpha Variant of SARS-CoV-2 Escapes IFITM Restriction and Is Necessary for Type I Interferon Resistance.
Cano-Mu?oz M et al. Int J Biol Macromol 2022; Novel chimeric proteins mimicking SARS-CoV-2 spike epitopes with broad inhibitory activity.
Kumar CS et al. ACS Infect Dis 2022; 8 (10):2119-2132 Virus-Like Particles of SARS-CoV-2 as Virus Surrogates: Morphology, Immunogenicity, and Internalization in Neuronal Cells.
Vanhulle E et al. Front Cell Infect Microbiol 2022; 12:989534 Carbohydrate-binding protein from stinging nettle as fusion inhibitor for SARS-CoV-2 variants of concern.
Li R et al. Commun Biol 2022; 5 (1):789 Conformational flexibility in neutralization of SARS-CoV-2 by naturally elicited anti-SARS-CoV-2 antibodies.
Almanza G et al. PLoS Pathog 2022; 18 (7):e1010686 Structure-selected RBM immunogens prime polyclonal memory responses that neutralize SARS-CoV-2 variants of concern.
Cheshenko N et al. Commun Biol 2022; 5 (1):1096 Cell-impermeable staurosporine analog targets extracellular kinases to inhibit HSV and SARS-CoV-2.
Application : ICC/IF
Richards A et al. iScience 2022; 25 (10):105146 SARS-CoV-2 infection of human pluripotent stem cell-derived liver organoids reveals potential mechanisms of liver pathology.
Application : ICC/IF
Nguyen LC et al. mBio 2022; 13 (5):e0241522 SARS-CoV-2 Diverges from Other Betacoronaviruses in Only Partially Activating the IRE1α/XBP1 Endoplasmic Reticulum Stress Pathway in Human Lung-Derived Cells.
Application : WB
Nguyen LC et al. bioRxiv 2022; SARS-CoV-2 diverges from other betacoronaviruses in only partially activating the IRE1α/XBP1 ER stress pathway in human lung-derived cells.
Application : WB
Suryawanshi RK et al. Nature 2022; 607 (7918):351-355 Limited cross-variant immunity from SARS-CoV-2 Omicron without vaccination.
Application : IHC-P
Yeh CT et al. Biomedicines 2022; 10 (11) Immunoglobulin Y Specific for SARS-CoV-2 Spike Protein Subunits Effectively Neutralizes SARS-CoV-2 Infectivity and Ameliorates Disease Manifestations In Vivo.
Ahmed-Belkacem A et al. Viruses 2022; 14 (9) Third Early "Booster" Dose Strategy in France of bnt162b2 SARS-CoV-2 Vaccine in Allogeneic Hematopoietic Stem Cell Transplant Recipients Enhances Neutralizing Antibody Responses.
Zhang Z et al. Nat Commun 2022; 13 (1):4399 Structure of SARS-CoV-2 membrane protein essential for virus assembly.
L?pez-Mu?oz AD et al. Sci Adv 2022; 8 (31):eabp9770 Cell surface SARS-CoV-2 nucleocapsid protein modulates innate and adaptive immunity.
Cheng Y et al. ACS Nano 2022; Protease-Responsive Peptide-Conjugated Mitochondrial-Targeting AIEgens for Selective Imaging and Inhibition of SARS-CoV-2-Infected Cells.
Chen IP et al. Cell Rep 2022; 40 (3):111088 Viral E protein neutralizes BET protein-mediated post-entry antagonism of SARS-CoV-2.
Gregoire C et al. Immunity 2022; 55 (7):1216-1233.e9 Viral infection engenders bona fide and bystander subsets of lung-resident memory B cells through a permissive mechanism.
Zhang Q et al. J Exp Med 2022; 219 (8) Recessive inborn errors of type I IFN immunity in children with COVID-19 pneumonia.
Anne Zebitz Eriksen et al. STAR Protoc 2022; 3 (2):101383 Protocols for SARS-CoV-2 infection in primary ocular cells and eye organoids.
Rumi Ueha et al. Front Cell Infect Microbiol 2022; 12:924725 Oral SARS-CoV-2 Inoculation Causes Nasal Viral Infection Leading to Olfactory Bulb Infection: An Experimental Study.
Application : IHC-P
Qian Wang et al. Cell Rep 2022; 39 (11):110924 Functional properties of the spike glycoprotein of the emerging SARS-CoV-2 variant B.1.1.529.
Application : WB
Anthony Fern?ndez-Casta?eda et al. Cell 2022; Mild respiratory COVID can cause multi-lineage neural cell and myelin dysregulation.
Application : IHC-P
Christian Setz et al. Int J Mol Sci 2022; 23 (12) Synergistic Antiviral Activity of Pamapimod and Pioglitazone against SARS-CoV-2 and Its Variants of Concern.
Application : ICC/IF
Ittipat Meewan et al. Pharmaceuticals (Basel) 2022; 15 (6) Discovery of Triple Inhibitors of Both SARS-CoV-2 Proteases and Human Cathepsin L.
Application : ICC/IF
Matthew Gagne et al. Cell 2022; 185 (9):1556-1571.e18 mRNA-1273 or mRNA-Omicron boost in vaccinated macaques elicits similar B cell expansion, neutralizing responses, and protection from Omicron.
Zijun Wang et al. Immunity 2022; Analysis of memory B cells identifies conserved neutralizing epitopes on the N-terminal domain of variant SARS-Cov-2 spike proteins.
Application : ICC/IF
Mengfei Chen et al. bioRxiv 2022; Evolution of nasal and olfactory infection characteristics of SARS-CoV-2 variants.
Application : IHC-Fr
Emiel Vanhulle et al. Biotechniques 2022; Intracellular flow cytometry complements RT-qPCR detection of circulating SARS-CoV-2 variants of concern.
Emiel Vanhulle et al. Antiviral Res 2022;:105342 SARS-CoV-2 Permissive glioblastoma cell line for high throughput antiviral screening.
Application : WB
Dapeng Li et al. bioRxiv 2022; Breadth of SARS-CoV-2 Neutralization and Protection Induced by a Nanoparticle Vaccine.
Application : IHC-P
Anthony Fern?ndez-Casta?eda et al. bioRxiv 2022; Mild respiratory SARS-CoV-2 infection can cause multi-lineage cellular dysregulation and myelin loss in the brain.
Application : IHC-Fr
Giuseppe Palladino et al. Mol Ther Methods Clin Dev 2022; 25:225-235 Self-amplifying mRNA SARS-CoV-2 vaccines raise cross-reactive immune response to variants and prevent infection in animal models.
Application : ELISA
Valeria Garcia-Flores et al. Nat Commun 2022; 13 (1):320 Maternal-fetal immune responses in pregnant women infected with SARS-CoV-2.
Application : IHC-P
Zijun Wang et al. bioRxiv 2022; Conserved Neutralizing Epitopes on the N-Terminal Domain of Variant SARS-CoV-2 Spike Proteins.
Application : ICC/IF
Chi-Ju Hsu et al. Microbiol Spectr 2022; 10 (1):e0236221 Dynamic Changes of the Blood Chemistry in Syrian Hamsters Post-Acute COVID-19.
Application : IHC-P
Setu M Vora et al. Proc Natl Acad Sci U S A 2022; 119 (9) Targeting stem-loop 1 of the SARS-CoV-2 5' UTR to suppress viral translation and Nsp1 evasion.
Application : FACS
Yasuo Ariumi et al. J Virol 2022; 96 (6):e0000222 Host Cellular RNA Helicases Regulate SARS-CoV-2 Infection.
Application : IP
Patrick Madden et al. Res Sq 2022; An immunoPET probe to SARS-CoV-2 reveals early infection of the male genital tract in rhesus macaques.
Application : IHC-Fr
Madden PJ et al. bioRxiv 2022; An immunoPET probe to SARS-CoV-2 reveals early infection of the male genital tract in rhesus macaques.
Application : IHC-Fr
Zijun Wang et al. Sci Transl Med 2021; 13 (577) Enhanced SARS-CoV-2 neutralization by dimeric IgA.
Application : ICC/IF
William M Schneider et al. Cell 2021; 184 (1):120-132.e14 Genome-Scale Identification of SARS-CoV-2 and Pan-coronavirus Host Factor Networks.
Application : WB
Paul Bastard et al. Sci Immunol 2021; 6 (62) Autoantibodies neutralizing type I IFNs are present in ~4% of uninfected individuals over 70 years old and account for ~20% of COVID-19 deaths.
Sung-Chan Wei et al. Front Immunol 2021; 12:771011 An Integrated Platform for Serological Detection and Vaccination of COVID-19.
Application : WB, ICC/IF, ELISA
H-Heinrich Hoffmann et al. Cell Host Microbe 2021; 29 (2):267-280.e5 Functional interrogation of a SARS-CoV-2 host protein interactome identifies unique and shared coronavirus host factors.
Application : WB
E A Rosado-Olivieri et al. bioRxiv 2021; Self-organized stem cell-derived human lung buds with proximo-distal patterning and novel targets of SARS-CoV-2.
Application : WB
Alice Lu-Culligan et al. Med (N Y) 2021; 2 (5):591-610.e10 Maternal respiratory SARS-CoV-2 infection in pregnancy is associated with a robust inflammatory response at the maternal-fetal interface.
Application : ICC/IF
Barbara Knoblach et al. Mol Biol Cell 2021; 32 (14):1273-1282 Peroxisomes exhibit compromised structure and matrix protein content in SARS-CoV-2-infected cells.
Application : WB, ICC/IF
Xiaoquan Li et al. PLoS Pathog 2021; 17 (9):e1009898 Ethacridine inhibits SARS-CoV-2 by inactivating viral particles.
Application : ICC/IF
L?pez-Mu?oz AD et al. bioRxiv 2021; Cell Surface SARS-CoV-2 Nucleocapsid Protein Modulates Innate and Adaptive Immunity.
Piscotta FJ et al. mSphere 2021; 6 (6):e0071121 Metabolites with SARS-CoV-2 Inhibitory Activity Identified from Human Microbiome Commensals.
Application : ICC/IF
Wagner TR et al. EMBO Rep 2021;:e53865 Biparatopic nanobodies protect mice from lethal challenge with SARS-CoV-2 variants of concern.
Application : ICC/IF
Yewdell J et al. Res Sq 2021; (Epub) Cell Surface SARS-CoV-2 Nucleocapsid Protein Modulates Innate and Adaptive Immunity.
Gagne M et al. Cell 2021; Protection from SARS-CoV-2 Delta one year after mRNA-1273 vaccination in rhesus macaques coincides with anamnestic antibody response in the lung.
Application : IHC-P
Saiz ML et al. Clin Epigenetics 2021; 13 (1):187 Epigenetic targeting of the ACE2 and NRP1 viral receptors limits SARS-CoV-2 infectivity.
Application : WB
Peng YC et al. Diagnostics (Basel) 2021; 11 (10) A Novel Rapid Test to Detect Anti-SARS-CoV-2 N Protein IgG Based on Shear Horizontal Surface Acoustic Wave (SH-SAW).
Application : WB
Kmiec D et al. PLoS Pathog 2021; 17 (10):e1009726 S-farnesylation is essential for antiviral activity of the long ZAP isoform against RNA viruses with diverse replication strategies.
Application : WB
Carapito R et al. Sci Transl Med 2021;:eabj7521 Identification of driver genes for critical forms of COVID-19 in a deeply phenotyped young patient cohort.
Application : ICC/IF
Cantwell AM et al. J Virol 2021; 95 (20):e0101021 Kinetic Multi-omic Analysis of Responses to SARS-CoV-2 Infection in a Model of Severe COVID-19.
Application : WB
Corbett KS et al. Nat Immunol 2021; 22 (10):1306-1315 mRNA-1273 protects against SARS-CoV-2 beta infection in nonhuman primates.
Application : IHC-P
Corbett KS et al. Science 2021; 373 (6561):eabj0299 Immune correlates of protection by mRNA-1273 vaccine against SARS-CoV-2 in nonhuman primates.
Application : IHC-P
Francica JR et al. Sci Transl Med 2021; 13 (607) Protective antibodies elicited by SARS-CoV-2 spike protein vaccination are boosted in the lung after challenge in nonhuman primates.
Application : IHC-P
Junqueira C et al. Res Sq 2021; (Epub) SARS-CoV-2 infects blood monocytes to activate NLRP3 and AIM2 inflammasomes, pyroptosis and cytokine release.
Verma R et al. mSystems 2021; 6 (4):e0064321 RNA-Protein Interaction Analysis of SARS-CoV-2 5' and 3' Untranslated Regions Reveals a Role of Lysosome-Associated Membrane Protein-2a during Viral Infection.
Application : WB
Eriksen A.Z. et al. Cell Stem Cell 2021; 28 (7):1205-1220 SARS-CoV-2 infects human adult donor eyes and hESC-derived ocular epithelium.
Application : IHC-P
DiPiazza A.T. et al. Immunity 2021; S1074-7613 (21):00262-4 COVID-19 vaccine mRNA-1273 elicits a protective immune profile in mice that is not associated with vaccine-enhanced disease upon SARS-CoV-2 challenge.
Application : IHC-P
Li D. et al. Cell 2021; S0092-8674 (21):00756-X In vitro and in vivo functions of SARS-CoV-2 infection-enhancing and neutralizing antibodies.
Application : IHC-P
Wang Z et al. Nature 2021; 595 (7876):426-431 Naturally enhanced neutralizing breadth against SARS-CoV-2 one year after infection.
Application : ICC/IF
Sci Immunol 2021; 6 (59) Pharmacological activation of STING blocks SARS-CoV-2 infection.
Sukhikh G et al. Viruses 2021; 13 (3) Vertical Transmission of SARS-CoV-2 in Second Trimester Associated with Severe Neonatal Pathology.
Application : IHC-P
Saunders KO et al. Nature 2021; 594 (7864):553-559 Neutralizing antibody vaccine for pandemic and pre-emergent coronaviruses.
Application : IHC-P
Park SH et al. PLoS Pathog 2021; 17 (5):e1009519 Interactions of SARS-CoV-2 envelope protein with amilorides correlate with antiviral activity.
Application : ICC/IF
Mellott DM et al. ACS Chem Biol 2021; 16 (4):642-650 A Clinical-Stage Cysteine Protease Inhibitor blocks SARS-CoV-2 Infection of Human and Monkey Cells.
Hoffmann H. et al. Cell 2021; 184 (1):133-148 TMEM41B Is a Pan-flavivirus Host Factor.
Application : ICC/IF
Caroline B Plescia et al. J Biol Chem 2021;:100103 SARS-CoV-2 viral budding and entry can be modeled using BSL-2 level virus-like particles
Application : WB
Rosado-Olivieri E. et al. Cell 2021; (Epub) Self-Organizing, Symmetry Breaking, Isogenic Human Lung Buds on Microchips Identify Alveolar Stem Cells as Novel Targets of SARS-CoV-2.
Li J et al. ACS Sens 2021; 6 (3):1270-1278 Microfluidic Magneto Immunosensor for Rapid, High Sensitivity Measurements of SARS-CoV-2 Nucleocapsid Protein in Serum.
Meyer M et al. bioRxiv 2021; (Epub) mRNA-1273 efficacy in a severe COVID-19 model: attenuated activation of pulmonary immune cells after challenge.
Application : IHC-P
Lu-Culligan A et al. medRxiv 2021; (Epub) SARS-CoV-2 infection in pregnancy is associated with robust inflammatory response at the maternal-fetal interface.
Application : ICC/IF
Sukhikh G et al. Viruses 2021; 13 (3):447 Vertical Transmission of SARS-CoV-2 in Second Trimester Associated with Severe Neonatal Pathology.
Application : IHC-P
Mor M et al. PLoS Pathog 2021; 17 (2):e1009165 Multi-clonal SARS-CoV-2 neutralization by antibodies isolated from severe COVID-19 convalescent donors.
Application : ICC/IF
Drake M Mellott et al. bioRxiv 2020; A cysteine protease inhibitor blocks SARS-CoV-2 infection of human and monkey cells.
Application : ICC/IF
Xiaoquan Li et al. bioRxiv 2020; Ethacridine inhibits SARS-CoV-2 by inactivating viral particles in cellular models.
Application : ICC/IF
Sara Schumann et al. Int J Mol Sci 2020; 21 (22) Immune-Modulating Drug MP1032 with SARS-CoV-2 Antiviral Activity In Vitro: A potential Multi-Target Approach for Prevention and Early Intervention Treatment of COVID-19.
Application : WB
Hoffmann HH et al. bioRxiv 2020; (Epub) TMEM41B is a pan-flavivirus host factor.
Mor M et al. bioRxiv 2020; (Epub) Multi-Clonal Live SARS-CoV-2 In Vitro Neutralization by Antibodies Isolated from Severe COVID-19 Convalescent Donors.
Wang Z et al. bioRxiv 2020; (Epub) Enhanced SARS-CoV-2 Neutralization by Secretory IgA in vitro.
Schmidt F et al. J Exp Med 2020; 217 (11) Measuring SARS-CoV-2 neutralizing antibody activity using pseudotyped and chimeric viruses.
Schmidt F et al. bioRxiv 2020; Measuring SARS-CoV-2 neutralizing antibody activity using pseudotyped and chimeric viruses.
William M Schneider et al. Cell 2020; (Epub) Genome-scale identification of SARS-CoV-2 and pan-coronavirus host factor networks.
Application : ICC/IF
Robbiani DF et al. Nature 2020; 584 (7821):437-442 Convergent antibody responses to SARS-CoV-2 in convalescent individuals.
Application : ICC/IF
Thomas Mandel Clausen et al. Cell 2020; S0092-8674 (20):31230-7 SARS-CoV-2 Infection Depends on Cellular Heparan Sulfate and ACE2.
Application : FACS
Robbiani DF et al. bioRxiv 2020; (Epub) Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals.
Application : ICC/IF
Kizzmekia S Corbett et al. N Engl J Med . 2020; (Epub) Evaluation of the mRNA-1273 Vaccine against SARS-CoV-2 in Nonhuman Primates.
Application : IHC-P
Davide F. Robbiani et al. bioRxiv 2020; (Epub) Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals.
Application : ICC/IF
Reactivity : SARS Coronavirus 2
SDS
PBS.pdf
Glycerol.pdf
Proclin.pdf
Package List Price ($)
$ 399
$ 169